Skip to main content

Advertisement

Table 2 Patient demographics and clinical characteristics

From: Cost burden associated with advanced non-small cell lung cancer in Europe and influence of disease stage

  Overall (N = 1030) Stage IIIB (n = 119) Stage IV (n = 911)
Mean agea, years (SD) 64.5 (10.1) 62.4 (10.6) 64.8 (10.0)
Male sex, n (%) 679 (65.9) 86 (72.3) 593 (65.1)
Mean body mass indexb, kg/m2 (SD) 24.0 (3.4) 24.4 (3.7) 24.0 (3.3)
Current/former smokerc, n (%) 787 (77.9) 98 (83.8) 689 (77.2)
Histological tumour type, n (%)
 Non-squamous 724 (70.3) 73 (61.3) 651 (71.5)
 Squamous 306 (29.7) 46 (38.7) 260 (28.5)
Mean disease durationd, weeks (SD) 35.9 (45.0) 27.6 (40.1) 37.1 (45.5)
Receiving second- or later-line therapye, n (%) 302 (29.5) 21 (17.6) 281 (31.1)
ECOG PS, n (%)
 0 200 (19.4) 24 (20.2) 176 (19.3)
 1 448 (43.5) 53 (44.5) 395 (43.4)
 2 282 (27.4) 29 (24.4) 253 (27.8)
 3 82 (8.0) 13 (10.9) 69 (7.6)
 4 18 (1.7) 0 (0.0) 18 (2.0)
Comorbiditiesf, n (%)
 COPD 362 (35.3) 36 (30.5) 326 (35.9)
 Hypertension 335 (32.7) 25 (21.2) 310 (34.1)
 Anxiety 158 (15.4) 25 (21.2) 133 (14.6)
 Hyperlipidaemia 131 (12.8) 16 (13.6) 115 (12.7)
 Depression 112 (10.9) 15 (12.7) 97 (10.7)
 Diabetes mellitus 112 (10.9) 15 (12.7) 97 (10.7)
 Emphysema 107 (10.4) 8 (6.8) 99 (10.9)
 Ischaemic heart disease 90 (8.8) 7 (5.9) 83 (9.1)
 Bronchitis 87 (8.5) 8 (6.8) 79 (8.7)
 Peripheral vascular disease 67 (6.5) 4 (3.4) 63 (6.9)
 None 314 (30.6) 35 (29.7) 279 (30.7)
Current employment statusg, n (%)
 Retired 614 (60.4) 66 (55.9) 548 (61.0)
 Working (full-time) 149 (14.7) 28 (23.7) 121 (13.5)
 Working (part-time) 65 (6.4) 4 (3.4) 61 (6.8)
 Unemployed 105 (10.3) 11 (9.3) 94 (10.5)
 Otherh 83 (8.2) 9 (7.6) 74 (8.2)
  1. COPD chronic obstructive pulmonary disease; ECOG PS Eastern Cooperative Oncology Group Performance Status; NSCLC non-small cell lung cancer; SD standard deviation
  2. Patient numbers given at top of column apply in all cases unless noted below
  3. aPatients reported to be 90+ years of age were assumed to be 90 years of age for the purposes of this analysis; overall, N = 1028; stage IV, n = 909
  4. bOverall, N = 926; stage IIIB, n = 108; stage IV, n = 818
  5. cOverall, N = 1010; stage IIIB, n = 117; stage IV, n = 893
  6. dOverall, N = 1015; stage IV, n = 896
  7. eOverall, N = 1022; stage IV, n = 903
  8. fComorbidities shown are those occurring in more than 5% of patients in either NSCLC stage subgroup; overall, N = 1026; stage IIIB, n = 118; stage IV, n = 908
  9. gOverall, N = 1016; stage IIIB, n = 118; stage IV, n = 898
  10. hIncludes homemakers and students